GBT
SLRN

Grove Bank & Trust’s ACELYRIN SLRN Stock Holding History

Grove Bank & Trust’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18
Closed -$183 – 691
2023
Q3 		$183 Buy
+18
New +$382 ﹤0.01% 736

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Grove Bank & Trust's SLRN Position: Q4 2023 in Review

Grove Bank & Trust sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 18 shares — an estimated $183 sold.

Grove Bank & Trust first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $183 in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

  • Grove Bank & Trust reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 18 ACELYRIN shares in Q4 2023, an estimated $183.
  • Grove Bank & Trust first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's ACELYRIN position peaked at $183 in Q3 2023.
  • 110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.